06/29/2026 | Companies

AACR Annual Meeting, advanced lung cancer, biotech, cancer drug development, cancer therapy, cancer treatment advancements, DOVBLERON, Eisai, Eisai partnership, EMA, European Medicines Agency, FDA approval, global healthcare, IBTROZI, International Recognition Procedure, Journal of Clinical Oncology, lung cancer research, MAA, Marketing Authorisation Application, metastatic cancer treatment, MHRA, non-small cell lung cancer, NSCLC treatment, Nuvation Bio, Nuvation Bio stock, NYSE NUVB, oncology, oncology innovation, pharmaceutical industry, Phase 2 clinical trials, precision medicine, rare cancer mutations, respiratory oncology, ROS1-positive NSCLC, ROS1+ lung cancer, taletrectinib, targeted therapy, TRUST-I, TRUST-II, UK regulatory approval